AstraZeneca and Mitsubishi Tanabe Pharma Collaborate in Diabetic Nephropathy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca and Mitsubishi Tanabe Pharma Collaborate in Diabetic Nephropathy


AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a three-year research collaboration in the area of diabetic nephropathy (failure of the kidney function due to diabetes). The aim of the research collaboration is to validate and progress novel research targets and molecules into clinical development.

The collaboration will span from target selection up to the delivery of small-molecule candidate drugs. Targets from each company’s early research portfolios have been identified as approaches of common interest and additional targets may be included under the collaboration at a later stage, if mutually desired. The research will be performed in parallel at AstraZeneca’s Cardiovascular and Metabolic Disease Innovative Medicines Unit (CVMD iMed) in Mölndal, Sweden, and at MTPC’s facilities in Japan. The companies believe that the collaboration will yield high quality candidate drugs much faster than working alone. There is no financial commitment for the research involved, and each party will contribute equal resource at their own cost.

“Diabetes is a core therapeutic area for AstraZeneca and a key growth platform for the company. With current approaches to diabetic nephropathy resulting in patients needing expensive and limited treatment options, such as dialysis or kidney transplantation, there’s a significant unmet clinical need," said Marcus Schindler, head of AstraZeneca's CVMD iMed, in a press release. "This collaboration will allow us to focus on early stage programs and generate decision-making data faster than working alone, ultimately providing a quicker expansion of our diabetic nephropathy portfolio for the treatment of chronic kidney disease."

Source: AstraZeneca

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here